NOVEL ANTIBODIES

• US 20160090416A1
• Filed: 05/28/2014
• Published: 03/31/2016
• Est. Priority Date: 05/28/2013
• Status: Active Application

• Current Assignee: Numab Innovation AG
• Original Assignee: Numab AG
• Inventors: GUNDE, Tea, MEYER, Sebastian, URECH, David
• Application Number:
  US14/893,497
• Publication Number:
  US 20160090416A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/626 Diabody or triabody
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to novel antibodies, which combine high affinity with high potency, particularly novel antibodies against a novel epitope.

Claims

1. An isolated antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3ε

, wherein said epitope comprises amino acid residue N4 as residue that is critical for binding.

3. The isolated antibody or functional fragment thereof of claim 1, that is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε

, particularly having an affinity to cynomolgus monkey CD3ε

that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε

.

10. The isolated antibody or functional fragment thereof of claim 1, wherein said binding to human CD3ε

is determined by determining the affinity of said antibody or functional fragment thereof in an IgG format to the purified extracellular domain of heterodimeric CD3ε

γ

of human origin using a surface plasmon resonance experiment, particularly using the following conditions;

MASS-1 SPR instrument (Siena Sensors);

capture antibody;

antibody specific for the Fc region of said IgG immobilized on an SPR-2 Affinity Sensor chip, Amine, Siena Sensors, using a standard amine-coupling procedure;

two-fold serial dilutions of human heterodimeric single-chain CD3ε

γ

extracellular domain ranging from 90 to 2.81 nM, injection into the flow cells for 3 min and dissociation of the protein from the IgG captured on the sensor chip for 5 min, surface regeneration after each injection cycle with two injections of 10 mM glycine-HCl, calculation of the apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (K_D) with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.

11. The isolated antibody or functional fragment thereof of claim 1, wherein said inducing of T-cell activation according to (iia) and/or (iic) is determined by determining the stimulation of CD69 expression by said isolated antibody or functional fragment thereof in an IgG format, particularly using the following conditions:

stimulation of Jurkat cells (100,000 cells/well) for 24 h with 20 μ

g/ml, 5 μ

g/ml and 1.25 μ

g/ml of said isolated antibody or functional fragment thereof in an IgG format after prior cross-linking by addition of 3-fold excess of an anti-IgG antibody (control;

OKT3 (BioLegend, Cat. No.

     317302) or TR66 (Novus Biologicals, Cat. No. NBP1-97446), cross-linking with rabbit anti-mouse IgG antibody (JacksonImmuno Research, Cat. No. 315-005-008));

cell staining for CD69 expression after stimulation using a Phycoerithrin (PE)-labeled antibody specific for human CD69 (BioLegend, Cat. No.

     310906), analysis with a flow cytometer (FACS aria III, Becton Dickinson);

negative control;

unstimulated Jurkat cells incubated with the cross-linking antibody stained with said anti-CD69 antibody.

12. The isolated antibody or functional fragment thereof of claim 1, wherein said longer lasting T-cell activation according to (iib) is determined by determining the time course of stimulation of CD69 expression by said isolated antibody or functional fragment thereof in an IgG format, particularly using the following conditions:

stimulation of 100,000 Jurkat cells/well for 0 h, 4 h, 15 h, 24 h, 48 h and 72 h with 5 μ

g/ml of said isolated antibody or functional fragment thereof in an IgG format anti-CD3 antibodies that have been cross-linked as in claim 10 and analysis of CD69 expression by flow cytometry as in claim 10.

13. The isolated antibody or functional fragment thereof of claim 1, wherein said inducing of T-cell activation according to (iia) and/or (iic) is determined by determining the stimulation of IL-2 secretion by said isolated antibody or functional fragment thereof in an IgG format, particularly using the following conditions:

stimulation of Jurkat cells (200,000 cells/well) with said isolated antibody or functional fragment thereof in an IgG format at a concentration of 5 μ

g/ml using 4 different assay setups;

(a) stimulation of Jurkat cells with said isolated antibody or functional fragment thereof in an IgG format cross-linked by addition of 3-fold higher concentrations of an anti IgG antibody (control;

OKT3 (BioLegend, Cat. No.

     317302) or TR66 (Novus Biologicals, Cat. No. NBP1-97446), cross-linking with rabbit anti-mouse IgG antibody (Jacksonlmmuno Research, Cat. No. 315-005-008));

(b) T-cell activation in absence of cross-linking antibody;

(c) immobilization of said cross-linking antibodies on the tissue culture plates by over-night incubation;

(d) immobilization of said isolated antibody or functional fragment thereof in an IgG format (or of control antibodies) on the tissue culture plate by over-night incubation in absence of cross-linking antibodies;

in each setup, one hour after addition, stimulation of cells with 10 ng/ml PMA and collection of supernatant after 24, 48 and 72 h to measure IL-2 release, quantified using a commercially available ELISA (BioLegend, Cat. No.

     431801).

15. The isolated antibody or functional fragment thereof of claim 1, wherein said antibody or functional fragment thereof is (i) a rabbit antibody or functional fragment thereof, or (ii) an antibody or functional fragment thereof obtained by humanizing the rabbit antibody or functional fragment thereof of (i).

16. The isolated antibody or functional fragment thereof of claim 1, wherein said isolated antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain comprising a combination of one CDR1, one CDR2 and one CDR3 region present in SEQ ID NOs:

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, particularly SEQ ID NOs;

4, 6, 10, and 22, more particularly SEQ ID NO;

10 and 22, particularly wherein said VH domain comprises framework domains selected from the framework domains present in SEQ ID NOs;

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, particularly SEQ ID NOs;

4, 6, 10, and 22, more particularly SEQ ID NO;

10 and 22, and a VL domain comprising a combination of one CDR1, one CDR2 and one CDR3 region present in SEQ ID NOs;

1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, particularly SEQ ID NOs;

3, 5, 9, and 21, more particularly SEQ ID NO;

9 and 21, particularly wherein said VL domain comprises framework domains selected from the framework domains present in SEQ ID NOs;

1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, particularly SEQ ID NOs;

3, 5, 9, and 21, more particularly SEQ ID NO;

9 and 21.

17. The isolated antibody or functional fragment thereof of claim 16, wherein said isolated antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain comprising the combination of CDR1, CDR2 and CDR3 present in one of SEQ ID NOs:

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, particularly SEQ ID NOs;

4, 6, 10, and 20, more particularly SEQ ID NO;

10 and 22, particularly wherein said VH domain comprises the combination of framework domains present in one of SEQ ID NOs;

2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, and 22, particularly SEQ ID NOs;

4, 6, 10, and 22, more particularly SEQ ID NO;

10 and 22, and a VL domain comprising the combination of CDR1, CDR2 and CDR3 present in one of SEQ ID NOs;

1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, particularly SEQ ID NOs;

3, 5, 9, and 21, more particularly SEQ ID NO;

9 and 21, particularly wherein said VL domain comprises the combination of framework domains present in one of SEQ ID NOs;

1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, particularly SEQ ID NOs;

3, 5, 9, and 21, more particularly SEQ ID NO;

9 and 21.

18. The isolated antibody or functional fragment thereof of claim 17, wherein said isolated antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain selected from SEQ ID NOs:

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, particularly SEQ ID NOs;

4, 6, 10, and 22, more particularly SEQ ID NO;

10 and 22, and a VL domain selected from SEQ ID NOs;

1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21, particularly SEQ ID NOs;

3, 5, 9, and 21, more particularly SEQ ID NO;

9 and 21.

19. The isolated antibody or functional fragment thereof of claim 18, wherein said isolated antibody or functional fragment thereof comprises an antigen-binding region comprising a VH/VL domain combination selected from SEQ ID NO:

1/SEQ ID NO;

2;

SEQ ID NO;

3/SEQ ID NO;

4;

SEQ ID NO;

5/SEQ ID NO;

6;

SEQ ID NO;

7/SEQ ID NO;

8, SEQ ID NO;

9/SEQ ID NO;

10, SEQ ID NO;

11/SEQ ID NO;

12, SEQ ID NO;

13/SEQ ID NO;

14, SEQ ID NO;

15/SEQ ID NO;

16, SEQ ID NO;

17/SEQ ID NO;

18, SEQ ID NO;

19/SEQ ID NO;

20, and SEQ ID NO;

21/SEQ ID NO;

22;

particularly SEQ ID NO;

3/SEQ ID NO;

4;

SEQ ID NO;

5/SEQ ID NO;

6;

SEQ ID NO;

9/SEQ ID NO;

10, and SEQ ID NO;

21/SEQ ID NO;

22;

more particularly SEQ ID NO;

9/SEQ ID NO;

10 and SEQ ID NO;

21/SEQ ID NO;

22.

20. An isolated antibody or functional fragment thereof binding to essentially the same epitope as the isolated antibody or functional fragment thereof of claim 16.

21. The isolated antibody or functional fragment thereof of claim 1, wherein said isolated antibody or functional fragment thereof comprises an antigen-binding region which is obtained by humanizing an antigen-binding region of claim 18.

22. A pharmaceutical composition comprising the isolated antibody or functional fragment thereof of claim 1, and optionally a pharmaceutically acceptable carrier and/or excipient.

23. A nucleic acid sequence or a collection of nucleic acid sequences encoding the isolated antibody or functional fragment thereof of claim 1.

24. A vector or a collection of vectors comprising the nucleic acid sequence or a collection of nucleic acid sequences of claim 23.

25. A host cell, particularly an expression host cell, comprising the nucleic acid sequence or the collection of nucleic acid sequences of claim 23, or a-vector or collection of vectors comprising said nucleic acid sequences or said collection of nucleic acid sequences.

26. A method for producing the isolated antibody or functional fragment thereof of claim 1, comprising the step of expressing the nucleic acid sequence or the collection of nucleic acid sequences encoding said isolated antibody or functional fragment thereof, or the vector or collection of vectors comprising said nucleic acid sequence or said collection of nucleic acid sequences, or the host cell, particularly an expression host cell comprising said nucleic acid sequences or said collection of nucleic acid sequences.

2. The isolated antibody or functional fragment thereof of claim 2, wherein said epitope further comprises amino acid residue E6 as residue that is involved in binding.

4. An isolated antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, is binding to human CD3 with a dissociation constant for monovalent binding of less than 3.0×

10<sup>−

8</sup> M, particularly less than 1.5×

10<sup>−

8</sup> M, more particularly less than 1.2×

10<sup>−

8</sup> M, and most particularly less than 1.0×

10<sup>−

8</sup> M.

9. The isolated antibody or functional fragment thereof of claim 4, wherein said epitope is located on the epsilon chain of human CD3.

14. The isolated antibody or functional fragment thereof of claim 4, wherein said isolated antibody or functional fragment thereof is cross-reactive with cynomolgus CD3.

5. An isolated antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, upon cross-linking, is inducing T-cell activation at least 1.5-fold stronger than antibodies OKT-3 or TR66 after 24 h of stimulation at an IgG concentration of 1.25 μ

g/ml.

6. An isolated antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, upon cross-linking, is resulting in T-cell activation, which lasts longer than with antibodies OKT-3 or TR66 as indicated by at least 1.5-fold greater increase in CD69 expression after 72 hours of stimulation at an IgG concentration of 1.25 μ

g/ml.

7. An isolated antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, upon cross-linking, is resulting in a dose-dependent homogeneous activation state of T-cells.

8. An isolated antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, (i) is binding to human CD3 with a dissociation constant for monovalent binding of less than 3.0×

10<sup>−

8</sup> M, particularly less than 1.5×

10<sup>−

8</sup> M, more particularly less than 1.2×

10<sup>−

8</sup> M, and most particularly less than 1.0×

10<sup>−

8</sup> M; and

(iia), upon cross-linking, is inducing T-cell activation at least 1.5-fold stronger than antibodies OKT-3 or TR66 after 24 h of stimulation at an IgG concentration of 1.25 μ

g/ml;

(iib) is resulting in T-cell activation, which lasts longer than with antibodies OKT-3 or TR66 as indicated by at least 1.5-fold greater increase in CD69 expression after 72 hours of stimulation at an IgG concentration of 1.25 μ

g/ml;

(iic) is resulting in a dose-dependent homogeneous activation state of T-cells; and

/or (iid) is specific for an epitope of human CD3ε

, wherein said epitope comprises amino acid residue N4 as residue that is critical for binding.